Grashma Vadakkel, PharmD PGY-2 Adult Oncology Pharmacy Resident Memorial Sloan Kettering Cancer Center
Bladder cancer is the sixth most common cancer in the United States. Patients with locally advanced or metastatic disease have poor long-term survival, especially those who have progressed after chemotherapy and immunotherapy. A new agent, enfortumab vedotin-ejfv (PADCEV, Astellas Pharma US, Inc.), ...